Skip to content
Open in App
Adalta logo

Adalta

web2

AdAlta is an Australian clinical stage biotechnology company developing experimental cellular i...

Symbol ยท 1AD
Company profile

About

AdAlta is an Australian clinical stage biotechnology company developing experimental cellular immunotherapies for solid tumors and investigating additional therapies based on its protein technology. Its development strategy involves licensing cell therapies originating in Asia and advancing them toward clinical development and potential commercialization in Western markets. Its EW-001 program involves an experimental CAR T cell therapy targeting advanced mesothelioma, developed in collaboration with Shanghai Cell Therapy Group. AdAlta is preparing manufacturing technology transfer and regulatory development activities in Australia. The company also maintains earlier research programs involving its i-body protein platform, including investigational candidates targeting fibrotic diseases and malaria. These programs remain development activities rather than established sales of approved medicines.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeSydneyPrimary symbol: 1AD
Expert coverage

Adalta profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment